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In Singapore, the incidence of breast cancer has doubled over the
past two decades, with an annual increase significantly higher in
premenopausal than post-menopausal women (5.7% vs 3.9%)
(Seow et al, 1996). Of note, this annual increase is almost four-
fold higher in premenopausal Singaporean Chinese women when
compared to cancer incidence rates from Western countries (dos
Santos Silva and Swerdlow, 1995). A hypothesis behind this
observation may be a birth cohort effect associated with lifestyle
changes like low parity and diet (Lee et al, 1991) as possible risk
modifiers in women with a genetic predisposition to breast cancer
(Narod et al, 1995; Chang-Claude et al, 1997).
In 1990, genetic linkage analysis of families with multiple cases
of early breast cancer led to the localization of the breast cancer
susceptibility gene BRCA1 to chromosome 17q (Hall et al, 1990)
and subsequently to the cloning of this gene (Miki et al, 1994).
Germline mutations of this gene appear to account for only about
40% of hereditary breast cancers and a minority of breast cancers
with a family history (Couch et al, 1997). As of 1997, more than
350 sequence alterations have been listed which may be associated
with breast cancer susceptibility (Breast Information Core, BIC).
These mutations are scattered throughout the coding sequence of
the gene, which is composed of 24 exons encoding for a 1863
amino acid protein. A majority are alterations that are predicted to
affect the structure of the resulting proteins and thus are likely to
be disease-causing mutations. In the case of BRCA1, approxi-
mately 40–50% of the alterations are frame-shift mutations, and
10–15% are non-sense mutations, both of which produce truncated
proteins. Mis-sense mutations that are probably associated with
increased risk of breast cancer account for 5–10% of the reported
mutations, and the remaining 30–40% of the alterations are of
unclear significance, either mis-sense or polymorphisms.
Mutations in BRCA1 are rare in the general Caucasian popula-
tion, apart from the Ashkenazi Jews (Streuwing et al, 1995).
Generally, results indicate about 5–6% of breast cancers under 40
years of age to be due to mutations in BRCA1 (Ford et al, 1995).
To date, no systematic studies of BRCA1 mutations in Chinese
patients with breast cancers have been reported. The objective of
this study was to determine the prevalence of BRCA1 mutations in
Chinese breast cancer patients in Singapore with early onset
disease or a positive family history.
METHODS AND MATERIALS
Patients and determination of family history
From 1990 to 1998, 85 consecutive unrelated patients presenting to
the National University Hospital were eligible for BRCA1 testing if
they had a diagnosis of breast cancer before the age of 40 years (i.e.
early onset), and/or at least one first-degree relative, or two second-
or third-degree relatives with either breast or ovarian cancer.
Of all eligible patients, nine women declined genetic testing. Of
the remaining 76 patients, 70 patients had early onset breast
cancer, 16 patients had breast cancer affected relatives, while ten
patients had both early onset breast cancer and affected relatives.
This study had institutional ethical committee approval and signed
written informed consent was obtained from each participant. The
family histories on number and age of relatives, together with
numbers of affected relatives and age of onset of cancers were
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determined by direct interviews by a single physician (JC). If
BRCA1 mutations were identified, BRCA1 analysis was offered
to first-degree female relatives of the patient.
Molecular studies
DNA isolation
Blood samples were obtained for the extraction of genomic DNA,
which was isolated from peripheral blood mononuclear cells using
standard procedures (Sambrook et al, 1989).
Single-strand conformation polymorphism and DNA
sequence analysis
Single-strand conformation polymorphism (SSCP) analysis using
primer pairs that span the BRCA1 coding region (BIC database)
and intron–exon boundaries was performed for all coding exons
except for exon 11. Polymerase chain reaction (PCR) amplifica-
tion of genomic DNA was carried out in 10-ml volumes
containing 50 ng of genomic DNA, 1.5 mM magnesium chloride,
50 mM potassium chloride, 10 mM Tris–HCl (pH 8.3), 200 mM
dNTPs (Promega, USA), 0.8 mM of each primer and 0.75 units of
Taq polymerase (Promega, USA). Amplification was for 35
cycles in a Perkin-Elmer 480 DNA thermal cycler (30 s at 94°C, 
1 min at the respective annealing temperature, and 1 min at 72°C,
with a 10-min extension at 72°C after the last cycle). A 1.2-ml
aliquot of the PCR product was diluted into 4.9 ml of denaturing
loading buffer (95% formamide, 10 mM sodium hydroxide,
0.05% xylene cyanol FF and 0.05% bromophenol blue), heated at
94°C for 5 min, cooled on ice for 5 min and loaded for electro-
phoresis. SSCP gels consisting of 0.53 Mutation Detection
Enhancement solution (FMC Bioproducts) in 0.63 Tris–borate
EDTA (TBE) buffer were run in 0.63 TBE buffer at 4 W for
18–22 h at 4°C. After electrophoresis, the SSCP gels were silver-
stained and the DNA bands of variant and wild-type mobility
were excised from the gels and eluted into 50 ml of TE (pH 8.0)
by incubating at 37°C for 2 h. The eluted DNA (10 ml) was used
as a template for subsequent PCR amplification. The PCR prod-
ucts were purified using the Wizard PCR Prep DNA Purification
System (Promega, USA) and double-stranded sequencing was
performed using the Sequenase PCR Product Sequencing Kit
(United States Biochemical, USA).
After completion of the sequencing reaction, the samples were
denatured at 82°C for 2–3 min, and 2.5 ml were loaded onto a
polyacrylamide gel containing 7M urea. Electrophoresis was at
60–70 W for 4 h at room temperature. Sequencing gels were fixed
with 10% methanol–10% glacial acetic acid, dried and exposed to
autoradiography overnight at room temperature. If mutations were
detected, a second SSCP-sequencing analysis was performed for
confirmation.
Protein transcription–translation assay
Protein transcription–translation (PTT) analysis was used to detect
truncating mutations in exon 11 (Cornelisse et al, 1995; Hogervorst
et al, 1996). Exon 11 was amplified in three overlapping fragments,
ranging in size from 1275 to 1600 bp, using previously published
primers (Plummer et al, 1995). The 5¢ oligonucleotide for each of
the three PCR fragments contained a T7 polymerase recognition
site, a Kozak consensus sequence and a start codon to allow the
transcription and translation of uncloned PCR products. PCR was
performed in 50 ml volumes, containing 13 PCR reaction buffer,
0.2 mM of each dNTP, 0.8 mM of each primer, 0.75 units of Taq
polymerase (Promega, USA) and 50 ng of template DNA. The
reactions were amplified under the following conditions: 1 cycle at
94°C for 3 min; 35 cycles at 94°C for 30 s; 52–58°C for 30 s and
72°C for 1 min with the final extension at 72°C for 10 min. PCR
products were purified, and the mRNA was translated into radio-
labelled peptides using the TnTTM T7 Coupled Reticulocyte Lysate
System or Wheat Germ System (Promega, USA). [35S]-methio-
nine/cysteine (NEN Research Products, USA) was used for
radioactive labelling of the translation products. The products were
size separated on 12% sodium dodecyl sulphate-polyacrylamide
(SDS-PAGE) gels. After electrophoreses, the gels were dried and
autoradiographed on HyperfilmTM (Amersham, UK) overnight at
–70°C. If truncations were detected, DNA sequencing was
performed as described above.
RESULTS
Patients’ characteristics
A total of 76 Chinese patients with breast cancer were analysed for
BRCA1 germline mutations. Seventy patients had breast cancer
under the age of 40 years, and 22 had breast cancer under the age
of 35 years. Sixteen patients had affected relatives, ten with breast
cancer under the age of 40 years and 6 at 40 years and above
respectively. The family histories of these women are summarized
in Table 1.
Table 1 BRCA1 mutations in patients with a positive family history
Patient Age Family history of cancer Mutations
no. (years) (age, years)
1 33 Mother: breast (50) C®T at nt4446
Maternal grandmother: breast (50)
Maternal aunt: breast (46)
2 39 Maternal aunt: breast (60s) 2732insT
Paternal cousin: breast (50s)
Father: lung (70)
Paternal cousin: brain (60)
3 32 Sister: breast (28) Not detected
Paternal cousin: breast (37)
4 Maternal grandmother: breast (50) Not detected
39 Paternal aunt: breast (60)
Paternal aunt: ovarian (70)
5 39 Sister: breast (39) Not detected
Paternal cousin: bilateral breast (39)
6 39 Sister: breast (40) Not detected
7 Maternal cousin: breast (40) Not detected
36 Maternal cousin: ovarian (40)
Maternal cousin: ovarian (40)
8 39 Sister: breast (43) Not detected
9 39 Sister: breast (40) Not detected
10 34 Mother: breast (44) Not detected
11 55 Sister: breast (50) Not detected
Niece: breast (50)
12 53 Daughter: breast (36) Not detected
13 52 Maternal grandmother: breast (70) Val191Ile
Maternal aunt: breast (50)
Maternal aunt: ovarian (35)
14 48 Mother: breast (50s) Not detected
15 52 Sister: breast (40) Not detected
16 40 Mother: breast (40) Not detected
Paternal cousin: bilateral (NK)Characterization of alterations in BRCA1 sequence
Prevalence
In the 70 patients with breast cancer under the age of 40 years, six
disease-causing mutations (8.6%) and three mis-sense mutations
of unknown significance were detected. In the 22 patients with
cancer under the age of 35 years, three disease-causing mutations
(13.6%) were found.
In those with affected relatives, two patients with breast cancer
before the age of 40 had disease-causing mutations, while a mis-
sense mutation was noted in a patient with breast cancer diagnosed
at 52 years (Table 1).
Disease-causing BRCA1 mutations
Of the six disease-causing mutations two occurred in patients
(BSF and MN) with early onset breast cancer and a positive family
history. The mutation found in patient BSF had not been published
previously and consisted of insertion of T at nt2732, resulting in
chain termination at codon 902 (Figure 1). The mutation in patient
MN was a non-sense mutation with a C to T substitution at nt4446,
resulting in a termination codon (Figure 2). The mother of MN
who had breast cancer, and the sister who had no history of cancer,
were found to harbour the same C®T mutation at nt4446. This
particular mutation has been previously described in 14 different
families including one family with 11 breast and ovarian cancers
(Couch et al, 1996).
Mis-sense mutations of unknown significance
An A®G mutation at nt3667 (Lys1183Arg) was detected in two
patients. One of them (TJG) also had a disease-causing mutation
(3378/3381delG). The other patient (YW) had an additional mis-
sense mutation at nt3300 (T®A, Ser 1040Thr).
A rare missense mutation was found in two other women (TGN,
TPC) with a G®A substitution (Val191Ile) in exon 9. Patient TGN
had breast cancer at 52 years and a positive family history, while
TPC had early onset breast cancer.
Polymorphisms
Twelve polymorphisms were identified representing sequence
changes in exon 3 (eight women at nt38, G®A mutation, Lys ®
Lys), in exon 13 (three women at nt1436, T®C mutation, Ser ®
Ser) and intron 18 (one woman at nt5272/5273, G®A mutation).
DISCUSSION
The prevalence of BRCA1 germline mutations in Singaporean
Chinese with early onset breast cancer under the age of 35 and 40
years were approximately 14% and 9% respectively. This is
similar to Western series, apart from the Ashkenazi Jews. In a UK
population-based study of 640 women, 3% of patients diagnosed
under 35 years and 5.3% of patients diagnosed under 40 years
were carriers of BRCA1 mutations (Ford et al, 1989). In a US
study, 7.5% of patients (six out of 80) under the age of 35 were
carriers of BRCA1 mutations (Langston et al, 1996). In a later
update of this series, 6.2% of patients under 35 years and 7.2% of
patients under 45 years with a first-degree family history were
found to be carriers of BRCA1 mutations (Malone et al, 1998).
Data from several authors suggest a limited role of BRCA1 muta-
tions in early onset breast cancer among Japanese patients (Inou et
al, 1995; Katagiri et al, 1996). The highest prevalence of BRCA1
mutations has been found in Ashkenazi Jewish women, with
approximately 20% of breast cancer patients under the age of 40
carrying the BRCA1 185delAG mutation (Streuwing et al, 1995).
In the present series of 16 Chinese patients with affected 
relatives, disease-causing BRCA1 mutations were found in two
patients who were diagnosed under the age of 40 years. Singapore
had practised a 2-child policy from the 1960s to the 1980s which
has limited the number of large family pedigrees. Our data suggest
that Singaporean Chinese patients with breast cancer and affected
relatives have a low probability of carrying germline BRCA1
mutations. This suggests that mutations in other cancer predisposi-
tion genes such as BRCA2, ataxia-telangiectasia gene (ATM) or
TP53 tumour suppressor gene may play a role in familial breast
cancers in Singaporean Chinese.
In our population, mutations were found mainly in exon 11
which represents 60% of the gene. The non-sense mutation C®T
at nt4446 of exon 13 was found in a patient and two first-degree
female relatives. The same mutation has been previously detected
in 14 different families (Couch et al, 1996). So far, studies with
polymorphic marker haplotypes within or close to BRCA1 have
suggested that almost all recurrent familial mutations in BRCA1
originate from a common founder (Neuhasen et al, 1996).
However, our observation of this C®T at nt4446 mutation in a
Chinese family suggests that this mutation may rather represent a
‘hot spot’ for mutagenesis.
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Table 2 BRCA1 mutations in patients with early onset breast cancer
Initials Age (years)  Exon Codon Nucleotide change Consequence Affected relatives
Disease-causing mutations
TSL 35 11A 464 1510delC Truncation at codon 474 N
WMC 37 11A 468 1523delG Truncation at codon 475 N
YSG 34 11B 770 2430insC Truncation at codon 776 N
TJG 39 11C 1088 3378/81delG Truncation at codon 1108 N
BSF 39 11B 871 2732insT Truncation at codon 902 Y
MN 33 13 1443 4446C®T Truncation at codon 1443 Y
Unclassified variants
TJG 39 11C 1183 3667A®G Lys1183Arg N
YW 39 11C 1183 3667A®G Lys1183Arg N
1040 3300T®A Ser1040Thr
TPC 38 9 119 690G®A Val191Ile N
del, deletion; ins, insertion.A mis-sense mutation in exon 9 (Val191Ile) has now been found
in three Chinese women with breast cancer, two in this series and
one in a Taiwanese Chinese woman with breast cancer at 34 years
(D Shattuck-Eidens, personal communication). Distinguishing
between disease-causing mis-sense mutations and rare polymor-
phisms remains problematic. Substitutions that occur in highly
conserved regions like the ring-finger domain, show segregation
with disease in high-risk families, and are not observed in controls
are typically classified as pathogenic. The mis-sense mutation
Val191Ile is located close to the ring-finger binding domain and
highly conserved as compared to murine BRCA1 (Sharan et al,
1995). Unfortunately, investigation of segregation of this mutation
with disease in our family with multiple cancers (TGN) was
unsuccessful as her relatives declined investigation.
Another unclassified variant Lys1183Arg was identified in two
women, of whom one had a definite truncated peptide at codon
1108. As such, this alteration is more likely to represent a poly-
morphism. Alternatively, Lys1183Arg may be present in linkage
disequilibrium with a definite disease-causing mutation (Dunning
et al, 1997). Finally, the polymorphisms observed in this series
have been noted by other investigators in control subjects and
patients (BIC database), and are unlikely to be associated with the
penetrant phenotypes normally seen in families with disease linked
to the BRCA1 region.
This is the first systematic study on BRCA1 mutations in a large
series of Chinese women with early onset and familial breast
cancer. The prevalence of mutations in patients with early onset
breast cancer is similar to that observed in Caucasian women. Only
few patients with a positive family history were carriers of BRCA1
mutations. Studies are in progress which will determine the preva-
lence of other cancer predisposition genes and the effect of
BRCA1 mutations on tumour phenotype and prognosis.
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